Fresh analysis indicates that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Published data in a prominent health publication points out that while obese individuals can lose about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"People using these drugs need to be aware of the potential of fast rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
That rate of regain suggests a reversion to original mass within about 18 months.
Comparing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.
Researchers point out that individuals who lose weight through dieting usually see a more gradual creep back—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists suggest the mode of action of the injections accounts for the heightened weight return.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations far above than normal could lead to the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, due to the high risk of weight regain, the treatment should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the results "underscore the persistent character of obesity," akin to managing diseases like hypertension.
User Experiences
Users who have come off the medication report a sudden return of cravings.
"It was like a switch activating and you're instantly ravenous," described an individual.
This challenge is worsened if individuals have not developed lasting dietary or behavioural changes during therapy.
Widespread Interest
Figures indicate that a significant number of people in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is greater among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic solution and lasting health benefits hinges on integrated behavioural support.
